NextFin news, On Wednesday, October 8, 2025, Swiss pharmaceutical companies are navigating a complex landscape as the Trump administration threatens to impose 100% tariffs on all patent-protected drugs imported into the United States. Major Swiss drugmakers such as Roche and Novartis have responded by committing billions of dollars to US manufacturing investments to secure exemptions from these tariffs.
Roche announced plans to invest $50 billion (CHF 40 billion) in the US over the next five years, while Novartis committed $23 billion to build and expand ten facilities in the US within the same period. These moves follow similar commitments by global pharma giants like Pfizer, which secured a deal with the US government to invest $70 billion and reduce drug prices in exchange for a three-year waiver from the tariffs.
The tariffs, initially set to take effect on October 1, 2025, target a wide range of medications, including treatments for weight loss and heart failure. The Trump administration's goal is to pressure pharmaceutical companies to lower drug prices in the US—the highest globally—and to increase domestic production, aligning with the administration’s slogan to "make America healthy again." However, the tariffs have not yet been implemented, and details on enforcement remain unclear.
While large multinational companies have dedicated policy teams negotiating directly with the US government, smaller Swiss pharmaceutical firms face a more precarious future. Many of these smaller companies, which often lack the scale or US manufacturing presence, are uncertain about how the tariffs will affect their exports. Industry insiders, speaking anonymously due to the sensitivity of the issue, indicate that the same tariff rules are expected to apply to all companies, regardless of size.
The Association of Pharmaceutical Companies in Switzerland (vips), representing smaller firms, has expressed concerns about the lack of clarity and the complex nature of pharmaceutical manufacturing, which often involves multiple sites and supply chains. The US market accounts for 50-60% of Swiss pharmaceutical exports, making the tariffs a significant threat to the industry’s revenue and research and development funding.
Some companies are exploring strategies to mitigate tariff impacts, such as using customs valuation rules to reduce the taxable value of exports or acting as non-resident importers to simplify compliance. However, experts warn that tariffs are only one aspect of the challenge, with US drug pricing policies playing a more critical role in shaping the industry's future.
Industry leaders warn that if profit margins are squeezed by tariffs and pricing pressures, investment in innovative drug development could decline, potentially altering the pharmaceutical business model significantly.
In summary, as of October 8, 2025, Swiss pharmaceutical giants are actively investing in US manufacturing to avoid punitive tariffs, while smaller Swiss drugmakers face uncertainty amid unclear tariff enforcement and potential financial impacts. The situation remains fluid as companies and the US government continue negotiations and preparations.
Source: SWI swissinfo.ch, published October 8, 2025.
Explore more exclusive insights at nextfin.ai.
